With rapid scientific advances in human genomics, proteomics, experimental therapeutics, and bioinformatics, the ability to optimize therapy for acute myelogenous leukemia (AML) and to tailor therapy for individual AML patients will become a reality. Such a targeted approach must not only focus on the biologic and genetic perturbations in leukemic cells that alter critical cellular pathways, but also on individual host genetic and biologic factors that predict for response or undue toxicity to specific therapeutic agents.
In terms of leukemia genetic markers, a number of new 'real-time' technologies are being developed that allow for the rapid identification of genetic and biologic abnormalities in leukemic cells at diagnosis, thereby facilitating patient stratification to different treatment regimens. Quantitative disease monitoring of the precise leukemia cell burden during therapy and in remission will also likely facilitate further treatment stratification and direct appropriate therapeutic intervention. Such quantitative disease monitoring tools are also likely to be useful in determining the effectiveness of new biologically directed therapies and new agents in early, as well as late phase clinical trials. New studies of global gene expression patterns using genomics and microarray approaches will also hopefully facilitate new diagnostic algorithms and define potential therapeutic targets, particularly when such technologies can be translated to functional assays that assess the functional state of critical biologic pathways in leukemic cells. Finally, the emerging field of pharmacogenetics and pharmacogenomics promises to identify risk-promoting and risk-modifying alleles for AML etiology and to determine those genetic polymorphisms that will be most useful in defining host response and toxicity to specific agents in AML patients.
Scientific studies have identified several critical biological pathways that are disrupted in leukemic cells and which present new opportunities and challenges for the identification of novel therapeutic targets. Such intracellular pathways include chromatin remodeling and transcriptional regulation, genome methylation, receptor modulation and signal transduction, drug resistance, and apoptosis. Equally important areas for the identification of new therapeutic targets include further investigation of the adhesive abnormalities of leukemic cells to underlying endothelium (particularly newly developed endothelium resulting from marrow neo-angiogenesis) and stroma in the marrow microenvironment.
Local chromatin remodeling is a critical event in the transcriptional regulation of human gene expression. As an evolving paradigm, proteins that regulate chromatin remodeling are disrupted in many forms of leukemia with translocations or inversions (Figure 1 ). Despite the striking cytogenetic heterogeneity of AML, dysregulated chromatin remodeling and transcriptional control appears to be a final common pathway linked to many of the recurrent chromosomal translocations and inversions in this disease. Such a final common pathway could thus be an important target for the development of new agents that could be effective in multiple genetic forms of this disease. Two primary mechanisms have been implicated in chromosome remodeling: the best described is histone acetylation and the second is ATPase-mediated DNA histone dissociation. 1, 2 In the genome, the higher ordered chromatin structure of the nucleosome contains a short stretch of doublestranded DNA wrapped around a histone octomer protein core (composed of two copies of each of the histone proteins 2A, 2B, 3 and 4). These histones have protein tails that tightly anchor associated chromatin and repress local transcription in the vicinity of the nucleosome. However, if these critical lysine residues are acetylated, the entire nucleosome structure relaxes thereby facilitating unwinding of local chromatin and transcriptional activation of adjacent genes. Thus histone deacetylation is associated with transcriptional repression while histone acetylation is associated with transcriptional activation (Figure 1 ). Such local histone acetylation and deacetylation is a dynamic event, mediated by key multiprotein nuclear complexes with enzymatic function.
As is well known, molecular investigations into acute promyelocytic leukemia (APL) first highlighted the critical role of transcriptional repression in leukemogenesis, leading to the development of the paradigm. 1 In normal cells, the retinoic acid receptor alpha (RAR␣), associated with its heterodimeric binding partner RXR, associates with the promoters of target genes. In the absence of all-trans retinoic acid (ATRA), the RAR␣/RXR transcriptional repressor recruits a multicomponent transcriptional repressor complex (Sin3a, N-CoR, HDAC) that includes a histone deacetylase (HDAC) that maintains local histone deacetylation and transcriptional repression. The binding of ATRA causes a release of this transcriptional repressor complex. Indeed, larger pharmacological doses of ATRA are necessary to overcome the increased transcriptional repressor of the PML-RAR␣/RXR complex characteristic of APL, compared to the normal RAR␣/RXR complex present in normal cells ( Figure 2 ).
1,2 While release of the transcriptional repressor complex is essential, it is not sufficient in the case of APL to initiate transcription. Rather a transcriptional activating complex, which includes a histone acetyl transferase (ACTR; associated with other adaptor proteins such as CBP/p300) must be recruited to initiate gene transcription. 2 Interestingly, histone deacetylases such as phenylbutyrate (as well as other new compounds such as trichostatin A and depsipeptide) which are being used as therapeutic agents in experimental clinical trials, inhibit the histone deacetylase, but do not alone activate transcription. 3 Such transcriptional activation also requires the presence of ATRA to induce the engagement of ACTR, thereby acetylating adjacent histones and promoting
Figure 1
Transcriptional regulation mediated by chromatin remodeling.
Figure 2
Transcriptional regulation mediated by histone deacetylation/acetylation. The retinoic acid receptors RAR and RXR, or the chimeric fusion PML-RAR␣ arising from the t(15;17) dimerize and bind to DNA in the promoter region of critical target genes; each of these receptors has a ligand binding domain for ATRA. In the absence of ATRA (left diagram), the RAR␣/RXR heterodimer recruits a transcriptional repressor complex containing the nuclear corepressor (NcoR), mSin3a, and a histone deacetylase (HD). This complex functions to deacetylate histones and represses transcription of the target gene. Histone deacetylase activity can also be inhibited by Trichostatin A or phenylbutyrate, now being introduced into clinical trials. ATRA binding to RAR␣/RXR or to the PML-RAR␣/RXR heterodimer (right diagram), results in a conformational change that releases the transcriptional repressor complex, allowing gene expression to be activated through recruitment of a transcriptional activator complex containing CBP/p300 and other proteins with histone acetyltransferase activity (ACTR). The resultant acetylation of adjacent chromatin relieves the transcriptional repression and activates gene expression. chromatin to relax and transcription factors to bind and initiate transcription (Figure 2) .
In addition to the PML-RAR␣ fusion in APL, a number of other fusion proteins arising from AML-associated recurrent chromosomal translocations also alter histone acetylation and chromatin remodeling. 1, 2, 4 The ETO moiety of the t(8;21) translocation has recently been shown to recruit the transcriptional repressor complex, thereby repressing transcription from genes normally activated by AML1. 4 In contrast, fusions involving MLL on chromosome 11q23, and translocations and inversions involving CBP on chromosome 8 (such as the t(8;16), t(11;16), and inv(8)) appear to interfere with recruitment of the transcriptional activator complex and ACTR (Figure 3) . Thus, transcription regulation is very complex and different leukemia genotypes may impact different components of these regulatory pathways. Distinguishing those forms of leukemia that result from active transcriptional repression from those which inhibit the recruitment of the transcriptional activation complex will be critical in the further development and application of novel inhibitors and pharmacologic mediators that affect the transcriptional machinery.
A number of critical questions can now be defined with respect to how these new transcriptional modulating agents will be implemented in the therapy of leukemia. Agents that interfere with histone deacetylation will likely be used in combination with agents (such as ATRA in the case of APL) that promote recruitment of transcriptional activating complexes and histone acetyl transferases. Histone deacetylase inhibitors, then, must be used in the context of other activating biologic compounds and probably other chemotherapies. Are these new therapeutic approaches appropriate for all AML patients, or should certain patients with specific genetic abnormalities be targeted? Should poor risk AML patients be treated first, where efficacy is going to be difficult to demonstrate? Finally, what biologic endpoints and assays can be developed to assess efficacy of these agents?
It has been well established that chromatin methylation is associated with transcriptional silencing, but the biochemical mechanism has been unclear. Interestingly however, the link between chromatin methylation and the recruitment of the same transcriptional repressor complexes (containing N-CoR, Sin3a, and HDAC moieties) has recently been made through the identification of methyl-binding proteins (MPB). 5 MBPs such as MECP1 and MECP2 bind selectively to methylated DNA where they recruit the same histone deacetylase complex described above that represses transcription through histone deacetylation. 5 Interestingly, inhibition of histone deacetylase leads to demethylation; many demethylating agents activate transcription, suggesting a tightly regulated interaction between transcriptional reagents and demethylating agents.
DNA methylation in cancer is complex since 5-methylcytosine residues themselves are intrinsically mutagenic. Indeed, increased DNA methyltransferase activity is a hallmark of most cancers. Protooncogenes can be activated by hypomethylation and tumor suppressor genes by hypermethylation. Interestingly, hypomethylation is being linked to defective chromosomal segregation, as well as gain and loss of whole chromosomes. Perhaps hypomethylation is an initiating event for the loss of chromosome 7 or 5, or the hyperdiploid state seen in childhood ALL.
DNA methyltransferase inhibitors such as 5-azacitidine have been shown to have efficacy in certain forms of leukemia and MDS, but in the past, we have not known how to identify which patients may benefit from such a therapeutic approach. To determine which patients would be likely to respond to these methylation-altering agents, PCR assays such as those based on bisulfite treatment of methylated DNA residues may be used to monitor the methylation state of particular promoters or to determine the methylation state of a particular patient at diagnosis. 6 In collaboration with Dr Jean-Pierre Issa of MD Anderson Cancer Center, we have analyzed the selec-tive methylation of the promoters of 14 genes that are hypomethylated or hypermethylated in AML. 7 These include cell cycle regulatory genes, genes involved in neoangiogenesis, genes mapping to specific chromosomes that we know play some role in leukemia, homeobox genes, and the multidrug resistance gene MDR1. Our data demonstrate that AMLs fall into three very broad categories: global hypomethylation of this set of promoters; intermediate levels of methylation; and an interesting group of patients that have extensive methylation of all promoters. The latter group has very good longterm survival. Such assays may in the future be useful in directing patients to appropriate therapy with demethylating agents or agents that actually promote methylation.
A number of automated technologies have been developed recently to quantitate tumor burden. While these technologies have traditionally been applied in the setting of minimal residual disease, recent studies in acute leukemia in children, as well as adults, reveal that determination of the quantitative disease burden at the end of induction may be useful in identifying those patients who are likely to have a sustained complete remission from those who are more likely to respond. 8 One of these technologies used to detect AML and ALL-associated chromosomal translocations is a fluorescence-based PCR assay (Taqman) using a specific fluorochrome-labeled oligonucleotide probe directed against the translocation fusion junction. 8 Such assays can relatively easily detect one in 100 000 to one in a million leukemic cells. We have recently applied this technology to a subgroup of 800 APL patients and assessed residual disease at the end of induction and consolidation. 9 Based upon the quantitative values of the amount of PML/RAR-␣ fusion mRNA at end of consolidation, we could predict which patients were more likely to relapse. In the future, these technologies for monitoring disease burden will be implemented earlier in the design of clinical trials to monitor the efficacy of novel therapies.
Gene expression analysis using microarrays may be useful in identifying genes associated with response or treatment failure in subsets of leukemia patients. By comparing differences in patterns of gene expression and biologic pathways between patients with the same chromosomal abnormalities, it may be possible to identify genes predictive of response. We are now analyzing the patterns of gene expression of 30 000 genes in cases with the same genotype, but different clinical outcomes. In our preliminary studies in AML using 15 000 arrays per patient sample, we can reliably distinguish gene expression profiles that are associated with either t(15;17) or t(8;21). Interestingly however, each patient within cytogenetically identical groups had distinct array profiles. Not surprisingly, leukemia cell lines analyzed at the same time were totally dissimilar from the primary AML tissues from the patients. It is our goal to continue to apply microarray technologies to large series of AML patients to define new classification schemes, identify profiles associated with specific forms of therapeutic response and resistance, and to identify novel therapeutic targets.
While AML arising in younger patients are characterized frequently by recurrent translocations and inversions, AML arising in more elderly patients is more genetically complex with associated chromosomal instability. In studies of AML patients over age 63 years, a genetic model similar to those proposed for colon cancer progression is more of a paradigm, with progressive mutation, complex karyotypic abnormalities, and drug resistance. In a recent Southwest Oncology Group study, S9126, the therapeutic modulation of MDR by addition of cyclosporine to standard chemotherapy has led to a dramatic impact on relapse-free survival in poor prognosis, Leukemia relapsed AML patients. 10 Response in this trial was related both to the expression of MDR1/P-glycoprotein and to functional drug efflux. Since a number of other ATP binding cassette transporter proteins like MDR1 have been identified, it is possible that other transporters are also being modulated by cyclosporine. Since MDR-negative patients also benefited from this therapeutic regimen, it is possible that cyclosporine is acting by other yet unidentified mechanisms of action.
Leukemia-associated genotypes promote disruption of normal signal transduction pathways. When transmembrane tyrosine kinase receptors are activated, they autophosphorylate and recruit adaptor proteins that recruit activators of the RAS pathway. Because many AML and CMML-associated translocations produce fusion proteins with increased tyrosine kinase activity with resultant RAS activation, various RAS inhibitors (such as isoprenylation or farnesyl transferase inhibitors) may play a role in AML therapy. In our recent studies, we have found that nearly 50% of older AML patients have mutations in either RAS or the transmembrane tyrosine kinase FLT3, which also leads to RAS activation. 11 These studies further suggest that agents targeting RAS or tyrosine kinases may have a broader efficacy in AML patients, particularly AML in the elderly.
The adhesive and supportive marrow macroenvironment, including stroma and endothelium provides survival factors to leukemic cells. AMLs have recently been demonstrated to produce vascular endothelial growth factor (VEGF), basic fibroblast growth factor (FGF), and other angiogenic factors promoting neoangiogenesis. 12, 13 Secretion of VEGF and basic FGF also stimulate the endothelium and the marrow stroma to release a number of cytokines critical for the survival of AML cells (such as IL-1␤) suggesting that adhesion dependence may be important for proliferation and survival of AML cells. This area of investigation is ripe for continued studies, not only to determine the role of the disruption of adhesion and angiogenesis in leukemogenesis, but as an area ripe for the development of novel therapeutic targets.
